-
Mashup Score: 3Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies - 3 day(s) ago
Purpose: This study sought to describe the changes in immune response to a third dose of either Pfizer’s or Moderna’s COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics Methods: This retrospective cohort study analyzed pre-3V and post-3V data on 493 patients diagnosed with hematologic malignancies across a large Midwestern health system between August 28, 2021, and November 1, 2021. For antibody testing, S1 spike antigen of the SARS-CoV-2 virus titer was used to determine serostatus. Results: Among 493 participants, 274 (55.6%) were seropositive both pre- and post-3V (+/+) while 115 (23.3%) seroconverted to positive from prior negative following the third dose (-/+). The remaining 104 (21.1%) were seronegative both before and after 3V (-/-). No participant was seropositive pre-3V and seronegative post-3V (+/-). Results showed a statistically significant increase in the proportion of seropositivity after receiving a third COVID
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies - 5 day(s) ago
Purpose: This study sought to describe the changes in immune response to a third dose of either Pfizer’s or Moderna’s COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics Methods: This retrospective cohort study analyzed pre-3V and post-3V data on 493 patients diagnosed with hematologic malignancies across a large Midwestern health system between August 28, 2021, and November 1, 2021. For antibody testing, S1 spike antigen of the SARS-CoV-2 virus titer was used to determine serostatus. Results: Among 493 participants, 274 (55.6%) were seropositive both pre- and post-3V (+/+) while 115 (23.3%) seroconverted to positive from prior negative following the third dose (-/+). The remaining 104 (21.1%) were seronegative both before and after 3V (-/-). No participant was seropositive pre-3V and seronegative post-3V (+/-). Results showed a statistically significant increase in the proportion of seropositivity after receiving a third COVID
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet-
Real World Third COVID19 Vaccine Dosing and Antibody Response in Patients with Hematologic Malignancies [Jul 18, 2022] @mtmdphd , Hallmeyer, @vrepublic , Liao, @mullane_michael @scmedlin , Copeland, @JimW9200 @JPCRR https://t.co/CnXLOfmBVw #COVID19nCancer #COVID19Vaccine #IDonc https://t.co/3iPQh8yrcm
-
-
Mashup Score: 0Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response - 16 day(s) ago
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers after standard pneumococcal vaccination (PV) in patients with MM and non-MM controls. Vaccination was standard for PV (PCV13 or PPV23), with laboratory testing at baseline and at 2, 4, 12 and 24 weeks after vaccination. Immunoglobulin G (IgG) antibodies to pneumococcal antigens were detected by ELISA. Prevaccination total IgG levels and IgG subclass levels were also measured by ELISA. Four of 6 controls responded with at least a 2-fold increase in antibody concentration; only 2 controls had a sustained increase in concentration. Six of 8 patients with MM had at least a 2-fold antibody increase; however, only 2 of these patients showed a sustained increase of antipneumococcal antibody. Respon
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Coordinating an Oncology Precision Medicine Clinic Within an Integrated Health System: Lessons Learned in Year One - 25 day(s) ago
Precision medicine is a term describing strategies to promote health and prevent and treat disease based on an individual’s genetic, molecular, and lifestyle characteristics. Oncology precision medicine (OPM) is a cancer treatment approach targeting cancer-specific genetic and molecular alterations. Implementation of an OPM clinical program optimally involves the support and collaboration of multiple departments, including administration, medical oncology, pathology, interventional radiology, genetics, research, and informatics. In this review, we briefly introduce the published evidence regarding OPM’s potential effect on patient outcomes and discuss what we have learned over the first year of operating an OPM program within an integrated health care system (Aurora Health Care, Milwaukee, WI) comprised of multiple hospitals and clinics. We also report our experience implementing a specific OPM software platform used to embed molecular panel data into patients’ electronic medical recor
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet-
Coordinating an Oncology #PrecisionMedicine Clinic w/in an Integrated Health System: Lessons Learned in Year 1 [1/28/19] @mtmdphd Godden, Wham @antonyruggeri @mullane_michael Wilson @shamsvirani Weissman, Ramczyk, Vanderwall @JimW9200 @Aurora_Cancer @JPCRR https://t.co/bxgjOfLhwk https://t.co/yd53qWlVFb
-
-
Mashup Score: 0Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response - 28 day(s) ago
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers after standard pneumococcal vaccination (PV) in patients with MM and non-MM controls. Vaccination was standard for PV (PCV13 or PPV23), with laboratory testing at baseline and at 2, 4, 12 and 24 weeks after vaccination. Immunoglobulin G (IgG) antibodies to pneumococcal antigens were detected by ELISA. Prevaccination total IgG levels and IgG subclass levels were also measured by ELISA. Four of 6 controls responded with at least a 2-fold increase in antibody concentration; only 2 controls had a sustained increase in concentration. Six of 8 patients with MM had at least a 2-fold antibody increase; however, only 2 of these patients showed a sustained increase of antipneumococcal antibody. Respon
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Refining a Postpandemic Approach to Cancer Screening - 1 month(s) ago
In introducing Volume 8, Issue 4 of Journal of Patient-Centered Research and Reviews — a specially themed issue comprised of several works focused on improving cancer screening processes in clinical practice — JPCRR editor and hematologist/oncologist Michael Thompson reflects on the current state of various screening modalities and how the pandemic has already begun to shape ongoing research in this area. A delicate balance must be struck between avoiding overtesting or overdiagnosis and identifying the presence of malignant tumors early enough to allow for successful treatment.
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Oncology precision medicine for hepatobiliary and pancreatic cancer: Insights and updates from a large community health system - 1 month(s) ago
By Geoffrey Bellini, Nicholas Sich, Jennifer Godden, et al., Published on 05/20/20
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet-
Oncology #PrecisionMedicine for hepatobiliary & pancreatic cancer: Insights & updates from a large community health system [5/20/20] Bellini Sich Godden @JimW9200 @WesleyPapenfuss Chevinsky @antonyruggeri @mtmdphd @Aurora_Health Scientific Day #44 https://t.co/66KdQ3TXf3 #hpbcsm https://t.co/UrUybQYmKb
-
-
Mashup Score: 0Coordinating an Oncology Precision Medicine Clinic Within an Integrated Health System: Lessons Learned in Year One - 1 month(s) ago
Precision medicine is a term describing strategies to promote health and prevent and treat disease based on an individual’s genetic, molecular, and lifestyle characteristics. Oncology precision medicine (OPM) is a cancer treatment approach targeting cancer-specific genetic and molecular alterations. Implementation of an OPM clinical program optimally involves the support and collaboration of multiple departments, including administration, medical oncology, pathology, interventional radiology, genetics, research, and informatics. In this review, we briefly introduce the published evidence regarding OPM’s potential effect on patient outcomes and discuss what we have learned over the first year of operating an OPM program within an integrated health care system (Aurora Health Care, Milwaukee, WI) comprised of multiple hospitals and clinics. We also report our experience implementing a specific OPM software platform used to embed molecular panel data into patients’ electronic medical recor
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet-
Coordinating an Oncology #PrecisionMedicine Clinic w/in an Integrated Health System: Lessons Learned in Year 1 [1/28/19] @mtmdphd Godden, Wham @antonyruggeri @mullane_michael Wilson @shamsvirani Weissman, Ramczyk, Vanderwall @JimW9200 @Aurora_Cancer @JPCRR https://t.co/bxgjOfLhwk https://t.co/yd53qWlVFb
-
-
Mashup Score: 3Patient Perspectives on the Use of Artificial Intelligence in Health Care: A Scoping Review - 1 month(s) ago
Purpose Artificial intelligence (AI) technology is being rapidly adopted into many different branches of medicine. Although research has started to highlight the impact of AI on health care, the focus on patient perspectives of AI is scarce. This scoping review aimed to explore the literature on adult patients’ perspectives on the use of an array of AI technologies in the health care setting for design and deployment. Methods This scoping review followed Arksey and O’Malley’s framework and Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Scoping Reviews (PRISMA-ScR). To evaluate patient perspectives, we conducted a comprehensive literature search using eight interdisciplinary electronic databases, including grey literature. Articles published from 2015 to 2022 that focused on patient views regarding AI technology in health care were included. Thematic analysis was performed on the extracted articles. Results Of the 10,571 imported studies, 37 articles were include
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Targeted Therapy for Cutaneous Melanoma: Beyond BRAF... - 1 month(s) ago
The development and regulatory approval of vemurafenib and dabrafenib for metastatic melanoma patients with activating BRAF mutations has demonstrated that personalized targeted therapy strategies can provide significant clinical benefit in this highly aggressive disease. However, these agents are not beneficial in patients who do not have activating BRAF mutations, representing over half of all melanoma patients. Recent studies have demonstrated that melanomas have the highest rate of somatic mutations among the major cancers. Based on this information, additional personalized treatment strategies are now in various stages of clinical development and testing. These efforts are being guided by the lessons learned in the development of effective therapeutics for BRAF, as well as a growing understanding of the molecular heterogeneity and drivers of this disease.
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet
Real World Third COVID19 Vaccine Dosing and Antibody Response in Patients with Hematologic Malignancies [Jul 18, 2022] @mtmdphd , Hallmeyer, @vrepublic , Liao, @mullane_michael @scmedlin , Copeland, @JimW9200 @JPCRR https://t.co/CnXLOfmBVw #COVID19nCancer #COVID19Vaccine #IDonc https://t.co/3iPQh8yrcm